We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04167345
Recruitment Status : Terminated (at Sponsor's discretion)
First Posted : November 18, 2019
Results First Posted : February 2, 2022
Last Update Posted : February 2, 2022
Sponsor:
Information provided by (Responsible Party):
Vertex Pharmaceuticals Incorporated

Brief Summary:
This study will evaluate the efficacy, safety and pharmacokinetics (PK) of VX-814 in PiZZ subjects.

Condition or disease Intervention/treatment Phase
Alpha 1-Antitrypsin Deficiency Drug: VX-814 Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 48 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of VX-814 in PiZZ Subjects
Actual Study Start Date : January 13, 2020
Actual Primary Completion Date : November 14, 2020
Actual Study Completion Date : November 14, 2020


Arm Intervention/treatment
Placebo Comparator: Parts A1, A2 and B Combined: Placebo
Participants received placebo matched to VX-814 in the treatment period for 28 days.
Drug: Placebo
Placebo matched to VX-814 for oral administration.

Experimental: Part A1: VX-814 100 milligrams (mg)
Participants received VX-814 100 mg every 12 hours (q12h) in the treatment period for 28 days.
Drug: VX-814
Tablet for oral administration.

Experimental: Part A1: VX-814 200 mg
Participants received VX-814 200 mg q12h in the treatment period for 28 days.
Drug: VX-814
Tablet for oral administration.

Experimental: Parts A1 and A2 Combined: VX-814 400 mg
Participants received VX-814 400 mg q12h in the treatment period for 28 days.
Drug: VX-814
Tablet for oral administration.

Experimental: Part B: VX-814 600 mg
Participants received VX-814 600 mg q12h in the treatment period for 28 days.
Drug: VX-814
Tablet for oral administration.




Primary Outcome Measures :
  1. Change in Plasma Functional Alpha-1 Antitrypsin (AAT) Levels [ Time Frame: From Baseline at Day 28 ]
  2. Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: Day 1 up to Week 8 ]

Secondary Outcome Measures :
  1. Change in Plasma Antigenic AAT Levels [ Time Frame: From Baseline at Day 28 ]
  2. Observed Pre-dose Plasma Concentration of VX-814 [ Time Frame: Pre-dose at Day 7, Day 14, Day 21, and Day 28 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Subjects must have a PiZZ genotype confirmed at screening
  • Plasma AAT levels indicating severe deficiency at screening

Key Exclusion Criteria:

  • History of a medical condition that could negatively impact the ability to complete the study
  • Solid organ, or hematological transplantation or is currently on a transplant list
  • History of use of gene therapy or RNAi therapy at any time previously

Other protocol defined Inclusion/Exclusion criteria may apply


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04167345


Locations
Show Show 28 study locations
Sponsors and Collaborators
Vertex Pharmaceuticals Incorporated
  Study Documents (Full-Text)

Documents provided by Vertex Pharmaceuticals Incorporated:
Study Protocol  [PDF] May 21, 2020
Statistical Analysis Plan  [PDF] November 11, 2020

Layout table for additonal information
Responsible Party: Vertex Pharmaceuticals Incorporated
ClinicalTrials.gov Identifier: NCT04167345    
Other Study ID Numbers: VX19-814-101
First Posted: November 18, 2019    Key Record Dates
Results First Posted: February 2, 2022
Last Update Posted: February 2, 2022
Last Verified: January 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Alpha 1-Antitrypsin Deficiency
Liver Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Subcutaneous Emphysema
Emphysema
Pathologic Processes